Timothy Hoffman

Featured in: Favicon

science.org

Articles

Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles

Aug 1, 2023 | science.org | Timothy Hoffman |Alexandre Martin |Annalisa M. VanHook |Varuna Nangia

Editor’s summaryFor patients with cancer driven by MAPK signaling, subsets of tumor cells often persist despite treatment with effective, targeted inhibitors. Some tumors have or develop mutations or bypass signaling to mediate drug resistance, but others lack such drivers. Hoffman et al. identified a common mechanism of tumor tolerance to MAPK pathway inhibitors.
Naked mole-rats slay zombies

Aug 1, 2023 | sciencemag.org | Timothy Hoffman |Alexandre Martin |Annalisa M. VanHook

(0)eLetters eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter. Log In to Submit a Response
Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles

Aug 1, 2023 | sciencemag.org | Timothy Hoffman |Alexandre Martin |Annalisa M. VanHook |Varuna Nangia

Editor’s summaryFor patients with cancer driven by MAPK signaling, subsets of tumor cells often persist despite treatment with effective, targeted inhibitors. Some tumors have or develop mutations or bypass signaling to mediate drug resistance, but others lack such drivers. Hoffman et al. identified a common mechanism of tumor tolerance to MAPK pathway inhibitors.
Exploiting an epigenetic switch in adrenal cancer

Jul 18, 2023 | science.org | Timothy Hoffman |Alexandre Martin |Annalisa M. VanHook |Leslie K. Ferrarelli

(0)eLetters eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter. Log In to Submit a Response